EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro

Silvia Martina Ferrari, Francesca Ragusa, Giusy Elia, Valeria Mazzi, Eugenia Balestri, Chiara Botrini, Licia Rugani, Armando Patrizio iD, Simona Piaggi, Concettina La Motta iD, Salvatore Ulisse iD, Camilla Virili und 2 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25126734 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Silvia Martina Ferrari und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy. Hauptthemen laut MEDLINE: Crizotinib, Thyroid Carcinoma, Anaplastic, Anaplastic Lymphoma Kinase, Cell Proliferation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic thyroid cancer (ATC) is one of the deadliest human cancers and represents

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CrizotinibThyroid Carcinoma, AnaplasticAnaplastic Lymphoma KinaseCell ProliferationProtein Kinase InhibitorsApoptosisThyroid NeoplasmsHumansMaleFemaleAntineoplastic AgentsMiddle AgedCell MovementAgedOncogene Proteins, FusionTumor Cells, CulturedCell Line, TumorCalmodulin-Binding ProteinsMembrane ProteinsNerve Tissue Proteins

Stichwörter der Autor:innen

STRN–ALK fusionanaplastic thyroid cancerapoptosiscrizotinibinvasionmigrationprimary cell culturesproliferationtyrosine kinase inhibitors

Substanzen

CrizotinibAnaplastic Lymphoma KinaseProtein Kinase InhibitorsAntineoplastic AgentsSTRN protein, humanALK protein, humanOncogene Proteins, FusionCalmodulin-Binding ProteinsMembrane ProteinsNerve Tissue Proteins

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
  • Department of Surgery, Medical and Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy.
  • Department of Emergency Medicine, Azienda Ospedaliero-Universitaria Pisana, 56126 Pisa, Italy.
  • Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.
  • Department of Pharmacy, University of Pisa, 56126 Pisa, Italy.
  • Department of Surgery, "Sapienza" University of Rome, 00161 Rome, Italy.

ORCID-Profile: Armando Patrizio, Concettina La Motta, Salvatore Ulisse, Alessandro Antonelli

Zitieren

APA

Ferrari, S. M., Ragusa, F., Elia, G., Mazzi, V., Balestri, E., Botrini, C., Rugani, L., Patrizio, A., Piaggi, S., La Motta, C., Ulisse, S., Virili, C., Antonelli, A., & Fallahi, P. (2024). Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126734

Vancouver

Ferrari SM, Ragusa F, Elia G, Mazzi V, Balestri E, Botrini C, et al. Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126734

BibTeX
@article{Ferrari2024,
  author = {Ferrari, Silvia Martina and Ragusa, Francesca and Elia, Giusy and Mazzi, Valeria and Balestri, Eugenia and Botrini, Chiara and Rugani, Licia and Patrizio, Armando and Piaggi, Simona and La Motta, Concettina and Ulisse, Salvatore and Virili, Camilla and Antonelli, Alessandro and Fallahi, Poupak},
  title = {Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25126734}
}
Kostenlos starten →